CytomX Therapeutics

OverviewSuggest Edit

CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics. The Company's Probody Platform allows to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, CytomX is an advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying its technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies.
TypePublic
Founded2008
HQSouth San Francisco, USMap
Websitecytomx.com
Employee Ratings4.3More
View Jobs (16)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)137(+49%)
Job Openings16
Revenue (FY, 2018)$59.5 M(-16%)
Share Price (Mar 2019)$10.8

Key People/Management at CytomX Therapeutics

D. Sean A. McCarthy

D. Sean A. McCarthy

President and Chief Executive Officer
Rachel Humphrey

Rachel Humphrey

Chief Medical Officer
Sridhar Viswanathan

Sridhar Viswanathan

Senior Vice President, Process Sciences and Manufacturing Operations
W. Kavanaugh

W. Kavanaugh

Chief Scientific Officer and Head of Research and Non-Clinical Development
Danielle Olander

Danielle Olander

Senior Vice President, Talent and Administrative Operations
Carol Verser

Carol Verser

Vice President, Intellectual Property
Show more

CytomX Therapeutics Office Locations

CytomX Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
343 Oyster Point Blvd #100
Show all (1)
Report incorrect company information

CytomX Therapeutics Financials and Metrics

CytomX Therapeutics Revenue

CytomX Therapeutics's revenue was reported to be $59.50 m in FY, 2018
USD

Revenue (FY, 2018)

59.5m

Net income (FY, 2018)

(84.6m)

EBIT (FY, 2018)

(77.9m)

Market capitalization (18-Mar-2019)

484.9m

Closing stock price (18-Mar-2019)

10.8

Cash (31-Dec-2018)

247.6m
CytomX Therapeutics's current market capitalization is $484.9 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

7.7m12.8m71.6m59.5m

Revenue growth, %

95%

General and administrative expense

12.6m19.9m25.6m33.5m

R&D expense

28.4m54.8m92.3m103.9m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.9m1.8m2.5m2.8m11.2m8.3m23.7m14.2m21.3m12.5m

General and administrative expense

4.1m5.0m4.6m5.0m5.7m6.0m6.2m7.4m9.0m8.1m

R&D expense

9.2m13.4m12.7m13.3m14.6m28.1m28.9m22.5m25.6m27.5m

Operating expense total

13.2m18.4m17.4m18.4m20.3m34.1m35.2m29.8m34.6m35.7m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

59.8m104.6m177.5m247.6m

Accounts Receivable

744.0k2.2m10.1m97.0k

Inventories

2.3m3.9m

Current Assets

189.8m188.1m388.6m445.5m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

36.2m67.9m62.4m59.8m85.7m272.9m284.2m142.2m132.9m259.8m

Accounts Receivable

406.0k316.0k285.0k240.0k213.0k158.0k40.2m81.0k25.1m56.0k

Inventories

4.8m

Current Assets

115.1m184.5m199.6m183.3m166.9m340.7m376.4m367.0m366.7m472.5m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(35.4m)(58.9m)(43.1m)(84.6m)

Depreciation and Amortization

1.2m1.7m1.6m1.9m

Accounts Payable

2.9m1.8m(2.4m)261.0k

Cash From Operating Activities

(27.4m)(2.0m)(75.5m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(11.9m)(16.0m)(14.2m)(14.7m)(8.3m)(10.2m)

Inventories

4.8m

Accounts Payable

2.7m5.0m1.4m517.0k3.7m6.4m2.9m
show all
USDY, 2018

Revenue/Employee

434.3k

Financial Leverage

3.5 x
Show all financial metrics

CytomX Therapeutics Operating Metrics

FY, 2016

Patents (Foreign)

4

Patents Pending

144

Phase I Trials Products

1

Preclinical Phase Products

4
Show all operating metrics
Report incorrect company information

Competitors

Althea
Healthcare - Subsidiary
Heidelberg Pharma
Healthcare - Public
MEI Pharma
Healthcare - Public
Oncopeptides
Healthcare - Public
Compare competitors

CytomX Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

CytomX Therapeutics News and Updates

February 27, 2019

CytomX Therapeutics Announces Full-Year 2018 Financial Results

Company to Host a Conference Call Today, February 27, 2019, at 5:00 p.m. EST / 2:00 p.m. PST Company to Host a Conference Call Today, February 27, 2019, at 5:00 p.m. EST / 2:00 p.m. PST
January 07, 2019

CytomX Therapeutics Announces Technology Acquisition From Agensys, Inc., an Affiliate of Astellas Pharma Inc.

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announc…
November 09, 2018

CytomX Therapeutics Presents CX-072 Clinical Translational Data at 2018 SITC Annual Meeting

 -Demonstrates Further Proof-of-Mechanism of Probody™ Platform –
October 22, 2018

CytomX Therapeutics Presents Clinical Data from Probody™ Platform and CX-072 at 2018 ESMO Annual Meeting

- Additional Data Supports PD-L1 Targeting Probody CX-072 as Well Tolerated with Antitumor Activity as Monotherapy and in Combination with Ipilimumab -
Report incorrect company information

CytomX Therapeutics Blogs

February 27, 2019

CytomX Therapeutics Announces Presentations at the American Association for Cancer Research Annual Meeting 2019

CytomX Therapeutics Announces Presentations at the American Association for Cancer Research Annual Meeting 2019 Content Import Wed, 02/27/2019 - 17:14 CytomX Therapeutics Announces Presentations at the American Association for Cancer Research Annual Meeting 2019 February 2…
February 26, 2019

CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probody™ Therapeutic Platform

CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probody™ Therapeutic Platform Content Import Tue, 02/26/2019 - 07:34 CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Program…
February 14, 2019

CytomX Therapeutics to Announce Full-Year 2018 Financial Results and Host Webcast Conference Call

CytomX Therapeutics to Announce Full-Year 2018 Financial Results and Host Webcast Conference Call jo-en.bautista… Thu, 02/14/2019 - 16:04 CytomX Therapeutics to Announce Full-Year 2018 Financial Results February 14, 2019 at 4:02 PM EST This release is a backfi…
February 05, 2019

CytomX Therapeutics Announces Senior Management Appointments

Leadership Team Further Strengthened with Additions of Nick Galli, J.D., as SVP, Chief Business Officer and Leslie Robbins, J.D. as SVP, Intellectual Property SOUTH SAN FRANCISCO, Calif. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused
January 30, 2019

CytomX Therapeutics to Host Research and Development Day on February 26, 2019

SOUTH SAN FRANCISCO, Calif. , Jan. 30, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today
December 20, 2018

CytomX Therapeutics Announces Changes to its Board of Directors

- President and CEO Sean McCarthy , D. Phil., Appointed to Additional Role of Chairman -   - Hoyoung Huh , M.D., Ph.D. Retiring from Board - - James R. Meyers , Former EVP at Gilead Sciences , Appointed to Board - SOUTH SAN FRANCISCO, Calif. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics,
Show more

 CytomX Therapeutics Frequently Asked Questions

  • When was CytomX Therapeutics founded?

    CytomX Therapeutics was founded in 2008.

  • Who are CytomX Therapeutics key executives?

    CytomX Therapeutics's key executives are D. Sean A. McCarthy, Rachel Humphrey and Sridhar Viswanathan.

  • How many employees does CytomX Therapeutics have?

    CytomX Therapeutics has 137 employees.

  • What is CytomX Therapeutics revenue?

    Latest CytomX Therapeutics annual revenue is $59.5 m.

  • What is CytomX Therapeutics revenue per employee?

    Latest CytomX Therapeutics revenue per employee is $434.3 k.

  • Who are CytomX Therapeutics competitors?

    Competitors of CytomX Therapeutics include Althea, Heidelberg Pharma and MEI Pharma.

  • Where is CytomX Therapeutics headquarters?

    CytomX Therapeutics headquarters is located at 343 Oyster Point Blvd #100, South San Francisco.

  • Where are CytomX Therapeutics offices?

    CytomX Therapeutics has an office in South San Francisco.

  • How many offices does CytomX Therapeutics have?

    CytomX Therapeutics has 1 office.

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more